New Method of Isolating Mesenchymal Stem Cells from Placenta
Private umbilical cord blood and tissue banking leader, Americord, announced on Oct. 17th that it has validated a revised process for the preservation of mesenchymal stem cells (MSCs) from placenta tissue. The new method greatly improves the success rate for preserving viable MSCs from Placenta Tissue, a service first developed in 2012.
MSCs are particularly valuable because of their ability to differentiate into a broad range of other cells found in the human body. Research has indicated that MSCs hold the promise of being able to someday treat debilitating conditions such as heart disease, type 1 diabetes, lung cancer and Parkinson's disease. Currently, clinical trials registered at ClinicalTrials.gov sum up to 367.
According to Americord, the new process has been shown to result in more effective harvesting of mesenchymal stem cells from placenta tissue. It greatly simplifies the collection process for delivery room medical personnel. Testing showed that 99% of the mesenchymal stem cells collected using the new process were viable.
H&B
Srhealth
